US › Healthcare

Estrella Immunopharma Inc. (ESLA)

US · Healthcare · Biotechnology

$0.70+0.57%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-2.3M
Profit YoY
-8.9%
EPS
$-0.05
EPS estimate
$-0.19

EPS came in at -0.05 against a street estimate of -0.19 — a beat of 73.7%.

Key statistics

Market cap
$30.7M
Forward P/E
0.0
P/B
4.13
Book value
$-0.12
EPS (TTM)
$-0.34
52-week high
$3.15
52-week low
$0.68
50-day MA
$0.97
200-day MA
$1.39
Beta
0.86

Analyst view

Analysts rate Estrella Immunopharma Inc. a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $12.00.

Shareholding

Insiders
60.61%
Institutions
12.15%

Largest institutional holders

FundStake
Armistice Capital, LLC9.53%
Vanguard Capital Management, LLC0.89%
Wells Fargo & Co0.61%
Geode Capital Management, LLC0.37%
Vanguard Fiduciary Trust Co0.15%
Renaissance Technologies Corp0.15%
State Street Corp0.10%
BlackRock Inc0.09%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Estrella Immunopharma Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.